CIK 0001061983
- Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 943291317
- Phone
- +1 650-624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,320,469
- in 18 filings, $12.5M under 10b5-1 plans
Net −$13,320,469. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blum Robert I −$9.7M President & CEO sold 34% of stake
- Malik Fady Ibraham −$1.3M EVP Research & Development sold 12% of stake
- Hessekiel Jeffrey −$795K Chief Legal & Admin Officer sold 14% of stake
- Callos Andrew −$702K EVP, Chief Commercial Officer sold 15% of stake
- PARSHALL B LYNNE −$631K Director sold 63% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-07 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion · Incentive Stock Option (Right to Buy) 10b5-1 | −14,186 | 0 | ||
| 2024-04-25 | HENDERSON JOHN T Director | Sale 10b5-1 | −10,562 | $64.54 | $682K | 32,070 |
| 2024-04-12 | Malik Fady Ibraham EVP Research & Development | Gift | −150 | 138,417 | ||
| 2024-04-09 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion 10b5-1 | +28,605 | $6.67 | $191K | 171,172 |
| 2024-04-09 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −28,605 | $74.31 | $2.1M | 142,567 |
| 2024-04-09 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −4,000 | $74.32 | $297K | 138,567 |
| 2024-04-09 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −28,605 | 0 | ||
| 2024-03-14 | Wong Robert VP, Chief Accounting Officer | Grant or award | +4,079 | 29,664 | ||
| 2024-03-14 | Wong Robert VP, Chief Accounting Officer | Grant or award · Incentive Stock Option (Right to Buy) | +1,403 | 1,403 | ||
| 2024-03-14 | Wong Robert VP, Chief Accounting Officer | Grant or award · Non-Qualified Stock Option (Right to Buy) | +3,308 | 3,308 | ||
| 2024-03-14 | Callos Andrew EVP, Chief Commercial Officer | Grant or award | +16,941 | 63,887 | ||
| 2024-03-14 | Callos Andrew EVP, Chief Commercial Officer | Grant or award · Non-Qualified Stock Option (Right to Buy) | +18,346 | 18,346 | ||
| 2024-03-14 | Callos Andrew EVP, Chief Commercial Officer | Grant or award · Incentive Stock Option (Right to Buy) | +1,224 | 1,224 | ||
| 2024-03-14 | Malik Fady Ibraham EVP Research & Development | Grant or award | +21,333 | 142,567 | ||
| 2024-03-14 | Malik Fady Ibraham EVP Research & Development | Grant or award · Incentive Stock Option (Right to Buy) | +1,541 | 1,541 | ||
| 2024-03-14 | Malik Fady Ibraham EVP Research & Development | Grant or award · Non-Qualified Stock Option (Right to Buy) | +23,103 | 23,103 | ||
| 2024-03-14 | Blum Robert I President & CEO | Grant or award | +61,490 | 461,221 | ||
| 2024-03-14 | Blum Robert I President & CEO | Grant or award · Incentive Stock Option (Right to Buy) | +1,568 | 1,568 | ||
| 2024-03-14 | Blum Robert I President & CEO | Grant or award · Non-Qualified Stock Option (Right to Buy) | +69,464 | 69,464 | ||
| 2024-03-06 | Wong Robert VP, Chief Accounting Officer | Shares withheld for taxes | −857 | $66.88 | $57K | 25,585 |
Page 34 of 45 · 885 trades